Clinical Trial

Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

Name: Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC — clinical trial record (NCT07294261)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is aimed to evaluate the efficacy and safety of the Garsorasib combination therapy in KRAS G12C mutant locally advanced and metastatic NSCLC

Trial Details

NCT Number	NCT07294261
Lead Sponsor	Sun Yat-sen University Collaborators: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions	Local Advanced or Metastatic NSCLC
Enrollment	69 participants
Start Date	2025-12-23
Primary Completion	2028-10-30 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-19